E. David Crawford, MD, presented “Patient’s Journey: Experience with mCRPC and the Lutetium (Pluvicto) Shortage” for the Grand Rounds in Urology audience in April 2023.
How to cite: Crawford, E. David. “Patient’s Journey: Experience with mCRPC and the Lutetium (Pluvicto) Shortage” April 2023. Accessed May 2024. https://grandroundsinurology.com/patients-journey-experience-with-mcrpc-and-the-lutetium-pluvicto-shortage/
Patient’s Journey: Experience with mCRPC and the Lutetium (Pluvicto) Shortage – Summary
E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, interviews his patient Lon, as well as Lon’s partner Kacy, about their treatment journey since Lon was diagnosed with advanced prostate cancer in 2018, as well as how the lutetium (Pluvicto) shortage has necessitated changes to his treatment plan. Lon first saw Dr. Crawford in 2018 and was diagnosed with advanced metastatic prostate cancer and has responded well to treatments in the ensuing years, including chemotherapy with docetaxel, ADT, radium 223, and sipuleucel-t. Lon discusses how he has undergone PSMA scans this year, which showed metastases in his liver, and while he would normally be a candidate for lutetium, the shortage in production has required an alternate treatment plan with cabazitaxel until it is available. Kacy talks about how amazed she is at the number of new treatments that have become available since his initial diagnosis, as well as how his positive response to all of them has allowed him to maintain a high quality of life, other than occasional fatigue, allowing them to keep up a frequent travel schedule and continue to living life at its fullest.
For more information on the lutetium (Pluvicto) shortage, see Dr. Crawford’s discussions with Edwin M. Posadas, MD, as well as Alan H. Bryce, MD, and Bryan A. Mehlhaff, MD.
